ArticleJournal of inflammation research2025
SCIN: A Key Driver in Chronic Atrophic Gastritis-Gastric Cancer Cascade with Implications for Immunity and Prognosis.
Article in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Gastric cancer (GC) is a major global health burden, and chronic atrophic gastritis (CAG), a key precancerous lesion in the Correa cascade, is critical in its pathogenesis. As a Ca² Methods: Transcriptomic data from TCGA and GEO were analyzed using R. WGCNA and ceRNA networks identified SCIN as the core RNA and its interacting miRNAs/lncRNAs. GSVA, GSEA, immune infiltration, and checkpoint analyses explored SCIN's immunological relevance. Prognostic value was assessed via Cox models and ROC curves. SCIN expression was validated in 28 human gastric tissues by RT-qPCR and Western blotting. Functional assays (CCK-8, Transwell, flow cytometry) investigated its role in GC cells. Results: SCIN expression significantly increased along normal mucosa→CAG→GC, with high diagnostic performance (AUC). Elevated SCIN correlated with poor survival and served as an independent prognostic factor. It was involved in immune-related pathways, modulated the TIME, and correlated with immune checkpoint markers. SCIN knockdown inhibited GC cell migration, enhanced apoptosis, and altered cell cycle. Conclusion: This study is the first to identify SCIN as a key molecular driver in the CAG-to-GC transition. SCIN represents a robust prognostic biomarker and a potential target for immunotherapeutic intervention in GC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.